Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124 · see citing works

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043 · see citing works

The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.

Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964 · see citing works

A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue

Yuan, M., Breitkopf, S. B., Yang, X., & Asara, J. M. (2012) · Nature Protocols · doi:10.1038/nprot.2012.024 · Cited by 1,122 · see citing works

Essential role for nuclear PTEN in maintaining chromosomal integrity

Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979 · see citing works

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 954 · see citing works

Nucleotide deficiency promotes genomic instability in early stages of cancer development

Bester, A. C., Roniger, M., Oren, Y. S., Im, M. M., Sarni, D., Chaoat, M., Bensimon, A., Zamir, G., Shewach, D. S., & Kerem, B. (2011) · Cell · doi:10.1016/j.cell.2011.03.044 · Cited by 858 · see citing works

Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation

Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821 · see citing works

Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome

Menon, S., Dibble, C. C., Talbott, G., Hoxhaj, G., Valvezan, A., Takahashi, H., Cantley, L., & Manning, B. (2014) · Cell · doi:10.1016/j.cell.2013.11.049 · Cited by 787 · see citing works

Maintaining genome stability at the replication fork

Branzei, D., & Foiani, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2852 · Cited by 786 · see citing works

Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation

Xu, X., Wagner, K., Larson, D. M., Ohler, Z. W., Li, C., Ried, T., Hennighausen, L. G., Wynshaw-Boris, A. J., & Deng, C. (1999) · Nature Genetics · doi:10.1038/8743 · Cited by 758 · see citing works

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 609 · see citing works

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer

Liu, X., Holstege, H. H., van der Gulden, H. M. L., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474 · see citing works

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465 · see citing works

Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling

Gewinner, C. A., Wang, Z. C., Richardson, A. L., Teruya‐Feldstein, J., Etemadmoghadam, D., Bowtell, D. D. L., Barretina, J., Lin, W. M., Rameh, L. E., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 456 · see citing works

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton

Hu, H., Juvekar, A., Lyssiotis, C. A., Lien, E. C., Albeck, J. G., Oh, D., Varma, G., Hung, Y. P., Ullas, S., Lauring, J. D., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.042 · Cited by 374 · see citing works

The molecular determinants of de novo nucleotide biosynthesis in cancer cells

Tong, X., Zhao, F., & Thompson, C. B. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.002 · Cited by 351 · see citing works

Activation of mammalian Chk1 during DNA replication arrest

Feijóo, C. G., Hall-Jackson, C. A., Wu, R., Jenkins, D., Leitch, J., Gilbert, D. M., & Smythe, C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104099 · Cited by 318 · see citing works

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G. A., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 303 · see citing works

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers

Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J. L., O'Toole, S. A., Millar, E. K. A., López‐Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283 · see citing works

Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer

Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M., & Ruggero, D. (2014) · Cell · doi:10.1016/j.cell.2014.03.052 · Cited by 260 · see citing works

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

Liu, P., Cheng, H.-L. M., Santiago, S., Raeder, M. B., Zhang, F., Isabella, A. J., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 258 · see citing works

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

Sommer, E. M., Dry, H., Cross, D. A. E., Guichard, S. M., Davies, B. R., & Alessi, D. R. (2013) · Biochemical Journal · doi:10.1042/bj20130342 · Cited by 158 · see citing works

SGK3 mediates INPP4B-dependent PI 3-Kinase signaling in breast cancer

Gasser, J. A., Inuzuka, H., Lau, A., Wei, W.-Y., Beroukhim, R., & Toker, A. (2014) · Molecules and Cells · doi:10.1016/j.molcel.2014.09.023 · Cited by 147 · see citing works

Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint

Kumar, D., Viberg, J., Nilsson, A. K., & Chabes, A. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq128 · Cited by 145 · see citing works

Replication Protein A and the Mre11·Rad50·Nbs1 Complex Co-localize and Interact at Sites of Stalled Replication Forks

Robison, J. G., Elliott, J., Dixon, K., & Oakley, G. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404750200 · Cited by 138 · see citing works

Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains

Miao, B., Skidan, I. N., Yang, J., Lugovskoy, A. A., Reibarkh, M., Long, K., Brazell, T., Durugkar, K. A., Maki, J. L., Ramana, C. V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004522107 · Cited by 136 · see citing works

Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway

Gorrini, C., Gang, B. P., Bassi, C., Wakeham, A. C., Baniasadi, S. P., Hao, Z., Li, W. Y., Cescon, D. W., Li, Y.-T., Molyneux, S. D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324136111 · Cited by 122 · see citing works

The continuous growth of vertebrate cells in the absence of sugar.

Wice, B. M., Reitzer, L., & Kennell, D. E. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43351-0 · Cited by 118 · see citing works

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

Nowsheen, S., Cooper, T. S., Stanley, J. A., & Yang, E. S.-H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046614 · Cited by 114 · see citing works

Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness

De, P. K., Sun, Y., Carlson, J. H., Friedman, L. S., Leyland-Jones, B. R., & Dey, N. (2014) · Neoplasia · doi:10.1593/neo.131694 · Cited by 111 · see citing works

Oncogenic signaling of class I PI3K isoforms

Denley, A., Kang, S. G., Kärst, U., & Vogt, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210918 · Cited by 105 · see citing works

Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations

Maor, S., Yosepovich, A., Papa, M. Z., Yarden, R. I., Mayer, D., Friedman, E., & Werner, H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.07.019 · Cited by 85 · see citing works

Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

Burga, L. N., Hu, H., Juvekar, A., Tung, N., Troyan, S. L., Hofstatter, E. W., & Wulf, G. M. (2011) · Breast Cancer Research · doi:10.1186/bcr2850 · Cited by 73 · see citing works

Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers

Burga, L. N., Tung, N., Troyan, S. L., Bostina, M., Konstantinopoulos, P. A., Fountzilas, H., Spentzos, D., Miron, A., Yassin, Y., Lee, B. T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2954 · Cited by 68 · see citing works

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer

Jang, N. Y., Kim, D. H., Cho, B. J., Choi, E. J., Lee, J.-S., Wu, H., Chie, E. K., & Kim, I. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1090-7 · Cited by 55 · see citing works

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment

Ip, L. R. H., Poulogiannis, G., Cia, F., Sasaki, J., Kofuji, S., Spanswick, V. J., Hochhauser, D., Hartley, J. A., Sasaki, T., & Gewinner, C. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3307 · Cited by 30 · see citing works

Targeting phospshatidylinositol 3-kinase signaling with novel phosphatidylinositol 3,4,5-triphosphate antagonists

Miao, B., & Degterev, A. (2011) · Autophagy · doi:10.4161/auto.7.6.15248 · Cited by 24 · see citing works

Mechanistic interplay among the M184I HIV-1 reverse transcriptase mutant, the central polypurine tract, cellular dNTP concentrations and drug sensitivity

Cor-Hosmer, S. K. V., Daddacha, W. B., & Kim, B. (2010) · Virology · doi:10.1016/j.virol.2010.07.028 · Cited by 13 · see citing works

The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism

Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137 · see citing works

mTOR signalling and cellular metabolism are mutual determinants in cancer

Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088 · see citing works

Targeting Metabolism for Cancer Therapy

Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works

PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer

Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743 · see citing works

Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets

Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 558 · see citing works

PI3K signaling in cancer: beyond AKT

Lien, E. C., Dibble, C. C., & Toker, A. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.007 · Cited by 446 · see citing works

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 388 · see citing works

Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination

Sivanand, S., Rhoades, S., Jiang, Q., Lee, J. V., Benci, J., Zhang, J., Yuan, S., Viney, I., Zhao, S., Carrer, A., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.008 · Cited by 295 · see citing works

The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer

Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89942 · Cited by 309 · see citing works

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30905-7 · Cited by 263 · see citing works

Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism

Reid, M. A., Allen, A. E., Liu, S., Liberti, M. V., Liu, P., Liu, X., Dai, Z., Gao, X., Wang, Q., Liu, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07868-6 · Cited by 228 · see citing works

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Dey, N., De, P. K., & Leyland-Jones, B. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 232 · see citing works

Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer

Li, Q., Qin, T., Bi, Z., Hong, H., Ding, L., Chen, J., Wu, W., Lin, X., Fu, W., Zheng, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15308-7 · Cited by 189 · see citing works

Connections between metabolism and epigenetics in cancers

Thakur, C., & Chen, F. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.006 · Cited by 172 · see citing works

Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer

Huang, T., Lampert, E. J., Coots, C., & Lee, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102021 · Cited by 161 · see citing works

Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol

Jung, Y. Y., Hwang, S. T., Sethi, G., Fan, L., Arfuso, F., & Ahn, K. S. (2018) · Molecules · doi:10.3390/molecules23112827 · Cited by 157 · see citing works

Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC–MS/MS

Yuan, M., Kremer, D. M., Huang, H., Breitkopf, S. B., Ben‐Sahra, I., Manning, B. D., Lyssiotis, C. A., & Asara, J. M. (2019) · Nature Protocols · doi:10.1038/s41596-018-0102-x · Cited by 155 · see citing works

Regulation of nucleotide metabolism in cancers and immune disorders

Ali, E. S., & Ben‐Sahra, I. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.03.003 · Cited by 131 · see citing works

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Darici, S., Alkhaldi, H., Horne, G. A., Jørgensen, H. G., Marmiroli, S., & Huang, X. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092934 · Cited by 130 · see citing works

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

Barchiesi, G., Roberto, M., Verrico, M., Vici, P., Tomao, F., & Tomao, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769280 · Cited by 96 · see citing works

Modulation of telomere protection by the PI3K/AKT pathway

Méndez‐Pertuz, M., Martínez, P., Blanco‐Aparicio, C., Gómez‐Casero, E., Garcı́a, A. B., Martinez-Torrecuadrada, J. L., Palafox, M., Cortés, J., Serra, V., Pastor, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01329-2 · Cited by 84 · see citing works

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 74 · see citing works

Emerging roles of nucleotide metabolism in cancer

Shi, D. D., Savani, M. R., Abdullah, K. G., & McBrayer, S. K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.008 · Cited by 76 · see citing works

Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications

Sheehan, B., Guo, C. W., Neeb, A., Paschalis, A., Sandhu, S. K., & Bono, J. S. D. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.06.006 · Cited by 67 · see citing works

A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair

Parrotta, R., Okonska, A., Ronner, M., Weder, W., Stahel, R. A., Penengo, L., & Felley‐Bosco, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.023 · Cited by 65 · see citing works

Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2

Bhardwaj, P., Iyengar, N. M., Zahid, H., Carter, K. M., Byun, D. J., Choi, M. H., Sun, Q., Savenkov, O., Louka, C., Liu, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade1857 · Cited by 58 · see citing works

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

Wang, L., Wang, D., Sonzogni, O., Ke, S., Wang, Q., Thavamani, A., Batalini, F., Stopka, S. A., Regan, M. S., Vandal, S. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111462 · Cited by 55 · see citing works

Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy

Han, B., Lin, X., & Hu, H. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-29 · Cited by 44 · see citing works

Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition

Luo, M., Zheng, F., Chen, W., Liang, Z.-M., Chandramouly, G., Tan, J., Willis, N. A., Chen, C.-H., Taveira, M. D. O., Zhou, X. Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2739 · Cited by 42 · see citing works

PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment

Shi, J.-J., Xing, H., Wang, Y., Zhang, X., Zhan, Q., Geng, M., Ding, J., & Meng, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.040 · Cited by 40 · see citing works

Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer

Liu, J. J., Yoon, S. M., Lee, H. W., Baik, M., Kim, O., Choi, Y. J., & Hur, S. Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143383 · Cited by 40 · see citing works

2α-Hydroxyalantolactone from Pulicaria undulata: activity against multidrug-resistant tumor cells and modes of action

Hegazy, M. F., Dawood, M., Mahmoud, N., Elbadawi, M., Sugimoto, Y., Klauck, S. M., Mohamed, N. S., & Efferth, T. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153409 · Cited by 40 · see citing works

Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk

Alemi, F., Sadigh, A. R., Malakoti, F., Elhaei, Y., Ghaffari, S. H., Maleki, M., Asemi, Z., Yousefi, B., Targhazeh, N., & Majidinia, M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30573 · Cited by 41 · see citing works

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer

Kim, K., Kim, J., Sung, J. H., Suh, K. J., Lee, J. Y., Kim, S. H., Lee, J., Kim, J. W., Kim, Y. J., Kim, J. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68998-w · Cited by 40 · see citing works

Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer

Du, W., Gao, A., Herman, J. G., Wang, L., Zhang, L., Jiao, S., & Guo, M. (2021) · Cancer Science · doi:10.1111/cas.14917 · Cited by 35 · see citing works

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells

Chopra, S. S., Jenney, A., Palmer, A. C., Niepel, M., Chung, M., Mills, C. E., Sivakumaren, S. C., Liu, Q., Chen, J.-Y., Yapp, C., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.11.001 · Cited by 34 · see citing works

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors

Lynch, J. T., Polanska, U. M., Delpuech, O., Hancox, U. J., Trinidad, A. G., Michopoulos, F., Lenaghan, C., McEwen, R. K., Bradford, J. R., Polanski, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0676 · Cited by 31 · see citing works

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

Lynch, J. T., Polanska, U. M., Hancox, U., Delpuech, O., Maynard, J., Trigwell, C., Eberlein, C. A., Lenaghan, C., Polański, R., Avivar‐Valderas, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0183 · Cited by 28 · see citing works

Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma

Wong, O. G., Li, J., & Cheung, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666815 · Cited by 24 · see citing works

Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA ‐mutant cervical carcinoma via the PI3K/AKT pathway

Ye, W., Lin, S., Zhi, W., Chu, T., Liu, B., Peng, T., Xu, M., Ding, W., Cao, C., & Wu, P. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28656 · Cited by 23 · see citing works

Metabolic Phenotyping of Anks3 Depletion in mIMCD-3 cells - a Putative Nephronophthisis Candidate

Schlimpert, M., Lagies, S., Budnyk, V., Müller, B., Walz, G., & Kammerer, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27389-y · Cited by 24 · see citing works

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells

Zhao, H., Yang, Q., Hu, Y., & Zhang, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6716 · Cited by 23 · see citing works

Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer

Yip, H. Y. K., Shin, S., Chee, A., Ang, C., Rossello, F. J., Wong, L. H., Nguyen, L. K., & Papa, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00496-y · Cited by 24 · see citing works

The signaling pathways that mediate the anti-cancer effects of caloric restriction

Lu, Y., Tao, F., Zhou, M., & Tang, K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.021 · Cited by 22 · see citing works

PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

McLean, B. A., Patel, V. B., Zhabyeyev, P., Chen, X., Basu, R., Wang, F., Shah, S., Vanhaesebroeck, B., & Oudit, G. Y. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010961 · Cited by 22 · see citing works

EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)

Konstantinopoulos, P. A., González-Martı́n, A., Cruz, F. M., Friedlander, M. L., Glasspool, R. M., Lorusso, D., Marth, C., Monk, B. J., Kim, J., Hinson, P., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0666 · Cited by 21 · see citing works

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth

Mishra, R., Yuan, L., Patel, H. M., Karve, A. S., Zhu, H., White, A., Alanazi, S., Desai, P. B., Merino, E. J., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042088 · Cited by 20 · see citing works

ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity

Ali, R., Alabdullah, M., Miligy, I., Normatova, M., Babaei‐Jadidi, R., Nateri, A. S., Rakha, E., & Madhusudan, S. (2019) · Cells · doi:10.3390/cells8101271 · Cited by 22 · see citing works

Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH‐A genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR

Varma, G., Seth, P., de Souza, P. C., Callahan, C. J., Pinto, J., Vaidya, M. V., Sonzogni, O., Sukhatme, V. P., Wulf, G. M., & Grant, A. K. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4560 · Cited by 20 · see citing works

Immunosuppressive Signaling Pathways as Targeted Cancer Therapies

Damane, B. P., Hull, R., Bida, M., Durandt, C., Mulaudzi, T. V., Chatziioannou, A. A., & Dlamini, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030682 · Cited by 20 · see citing works

NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression

Reddy, T. P., Puri, A., Guzman‐Rojas, L., Thomas, C. G., Qian, W. P., Zhou, J., Zhao, H., Mahboubi, B., Oo, A., Cho, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54651-x · Cited by 18 · see citing works

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors

Lee, E. K., & Matulonis, U. A. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773791 · Cited by 16 · see citing works

Serial-omics of P53−/−, Brca1−/− Mouse Breast Tumor and Normal Mammary Gland

Breitkopf, S. B., Taveira, M. D. O., Yuan, M., Wulf, G. M., & Asara, J. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15132-y · Cited by 15 · see citing works

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors

Chen, Z., Chen, C., Zhou, T., Duan, C., Wang, Q., Zhou, X., Zhang, X., Wu, F., Hua, Y., & Lin, F. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01427-0 · Cited by 15 · see citing works

Shutting down the power supply for DNA repair in cancer cells

van Vugt, M. A. T. M. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201701026 · Cited by 13 · see citing works

Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants

Ghodsinia, A., Lego, J.-A. M. T., & Garcia, R. L. (2020) · Cells · doi:10.3390/cells9051116 · Cited by 13 · see citing works

Cotargeting BET proteins overcomes resistance arising from PI3K / mTOR blockade‐induced protumorigenic senescence in colorectal cancer

Lee, H., Lee, S., & Cho, K. (2020) · International Journal of Cancer · doi:10.1002/ijc.33047 · Cited by 12 · see citing works

Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)

Jin, N. Y., Xia, Y., & Gao, Q. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5476 · Cited by 12 · see citing works

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies

Nerone, M., Rossi, L. A., Condorelli, R., Ratti, V., Conforti, F., Palazzo, A., & Graffeo, R. (2023) · Cancers · doi:10.3390/cancers15133305 · Cited by 10 · see citing works

DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes

Huang, N., Yang, S., Shi, W., Guo, J., Zhang, Z., He, Q., Wu, L., Li, X., & Xu, F. (2023) · iScience · doi:10.1016/j.isci.2023.106962 · Cited by 9 · see citing works

Nanoemulsion of myricetin enhances its anti-tumor activity in nude mice of triple-negative breast cancer xenografts

Sharma, P., Rai, Y., Khan, M. A., Bhatt, A. N., Najmi, A. K., Chaturvedi, S., Akhtar, M., & Mishra, A. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1563076 · Cited by 8 · see citing works

ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair

Jiao, W., Zhu, S., Shao, J., Zhang, X., Xu, Y., Zhang, Y., Wang, R., Zhong, Y., & Kong, D. (2022) · BioMed Research International · doi:10.1155/2022/8568528 · Cited by 8 · see citing works

Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer

Tsang, T., He, Q., Cohen, E. B., Stottrup, C., Lien, E. C., Zhang, H., Lau, C. G., & Chin, Y. R. (2022) · Cancers · doi:10.3390/cancers14205006 · Cited by 8 · see citing works

Beclin 1-Mediated Autophagy Is Potentiated by an Interaction with the Neuronal Adaptor FE65

Chan, W. W. R., Chow, J., Chau, D. D., Zhai, Y., & Lau, K. (2025) · Biology · doi:10.3390/biology14010097 · Cited by 6 · see citing works

Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents

Lee, E. K., & Liu, J. F. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_10 · Cited by 6 · see citing works

Transcriptome and Metabolome Analyses Provide Insight into the Glucose-Induced Adipogenesis in Porcine Adipocytes

Jiang, S., Zhang, G. H., Miao, J., Wu, D., Li, X., Li, J., Jian-xiong, L., & Gun, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030131 · Cited by 5 · see citing works

Untargeted stable isotope-resolved metabolomics to assess the effect of PI3Kβ inhibition on metabolic pathway activities in a PTEN null breast cancer cell line

Lackner, M., Neef, S. K., Winter, S., Beer‐Hammer, S., Nürnberg, B., Schwab, M. G., Hofmann, U., & Haag, M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1004602 · Cited by 5 · see citing works

PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro

Perry, J. R., Genenger, B., Thind, A. S., Ashford, B., & Ranson, M. (2024) · Cancers · doi:10.3390/cancers16020370 · Cited by 5 · see citing works

β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models

Korovina, I., Elser, M., Borodins, O., Seifert, M., Willers, H., & Cordes, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116217 · Cited by 5 · see citing works

Variability of Fragments of Nuclear Brca1 Gene, Exon 11, and Mitochondrial Cox1 Gene in House Mice Mus musculus

Богданов, А. С., Maltsev, А. N., Котенкова, Е. В., Malikov, V. G., Lissovsky, A. A., Стахеев, В. В., Darvish, J., & Castiglia, R. (2020) · Molecular Biology · doi:10.1134/s0026893320020028 · Cited by 5 · see citing works

Methylation of NRIP3 Is a Synthetic Lethal Marker for Combined PI3K and ATR/ATM Inhibitors in Colorectal Cancer

Zhang, M., Li, X., Herman, J. G., Gao, A., Wang, Q., Yao, Y., Shen, F., He, K., & Guo, M. (2024) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000682 · Cited by 4 · see citing works

Metabolic perturbations caused by depletion of nephronophthisis factor Anks6 in mIMCD3 cells

Schlimpert, M., Lagies, S., Müller, B., Budnyk, V., Blanz, K. D., Walz, G., & Kammerer, B. (2019) · Metabolomics · doi:10.1007/s11306-019-1535-0 · Cited by 4 · see citing works

Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells

Hiroki, H., Akahane, K., Inukai, T., Morio, T., & Takagi, M. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03520-8 · Cited by 4 · see citing works

MCT4 regulates de novo pyrimidine biosynthesis in GBM in a lactate-independent manner

Spina, R., Voss, D. M., Yang, X., Sohn, J. W., Vinkler, R., Schraner, J., Sloan, A. R., Welford, S. M., Avril, N. E., Ames, H. M., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz062 · Cited by 3 · see citing works

UBR5 antagonizes DNA damage to enhance the doxorubicin resistance of triple-negative breast cancer by p38 signaling

Zhang, H., Shao, X., Wang, X., Pang, J., Peng, S., Wang, S., Feng, X., & Liao, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003061 · Cited by 2 · see citing works

Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors

Wang, L., Sardella, B., Aronson, E. K., Liu, Z., Li, X., Wulf, G. M., & Heng, Y. J. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00892-6 · Cited by 2 · see citing works

Energy Deficiency‐Induced ATG4B Nuclear Translocation Inhibits PRMT1‐Mediated DNA Repair and Promotes Leukemia Progression

Wang, Z., Zhang, X., Zhou, Y., Lin, S., Fu, Y., Liu, H., Gao, Q., Xiao, Y., Yin, Z., Liu, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202509838 · Cited by 2 · see citing works

Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy

Fernández, A. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.002 · Cited by 2 · see citing works

Comprehensive live-cell imaging analysis of cryptotanshinone and synergistic drug-screening effects in various human and canine cancer cell lines

Bittner, M. L., Lopes, R., Jianping Hua, A., Chao Sima, A., Datta, A. A., & Wilson-Robles, H. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0236074 · Cited by 2 · see citing works

Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

Bergsma, P., Porazinski, S. R., Istadi, A., Fajardo, D. C., Mahmood, Y., Lombardi, S., Schuhmacher, D., Barraclough-Franks, H., Strbenac, D., Dennis, C. V., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0704 · Cited by 1 · see citing works

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

Abdulkareem, N. M., Jiang, Y., Qi, Y., Liu, X., Zhang, X., Cai, S., Shao, J., Jeter-Jones, S. L., Rinkenbaugh, A. L., Cheng, C.-C., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2513742123 · Cited by 1 · see citing works

Изменчивость фрагментов экзона 11 ядерного гена Brca1 и митохондриального гена Cox1 у домовых мышей Mus musculus

Богданов, А. С., Maltsev, А. N., Котенкова, Е. В., Malikov, V. G., Lissovsky, A. A., Стахеев, В. В., Darvish, J., & Castiglia, R. (2020) · Molecular Biology · doi:10.31857/s0026898420020020 · Cited by 1 · see citing works

Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer cellsPreprint

Chopra, S. S., Jenney, A., Palmer, A. C., Niepel, M., Chung, M., Mills, C. E., Sivakumaren, S. C., Liu, Q., Chen, J.-Y., Yapp, C., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/700625 · Cited by 1 · see citing works

Targeted therapy to annihilate the immune-evading phenotype in cancer evolution

Fernández, A. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1450867

Faculty Opinions recommendation of Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism.

van Beek, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734674681.793561438

Obesity promotes breast epithelium DNA damage in BRCA mutation carriersPreprint

Bhardwaj, P., Iyengar, N. M., Zahid, H., Carter, K. M., Byun, D. J., Choi, M. H., Sun, Q., Savenkov, O., Louka, C., Liu, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.29.502090

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalencePreprint

Petrella, P. E., Chen, J. W., Ravelo, G. O., & Cosgrove, B. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.28.591568

MicroRNA spatial profiling for assessing drug efficacy in BRCA1 -related triple-negative breast tumorsPreprint

Mohd, O. N., Wang, L., Sardella, B., Jou, D., Wulf, G. M., Slack, F. J., Heng, Y. J., & Doyle, P. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.698824

Targeting IP6 signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance

Lee, S., Seo, Y., Jeong, S., Chung, Y., Kong, S., Kim, M., Rhlee, J. H., Um, S., Mathew, B. P., Maiti, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71421-z

Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in PIK3CA-Wildtype Platinum-Resistant Endometrial Cancer

Shih, C.-T., Ibanez, K. R., Lee, J.-M., & Huang, T.-T. (2026) · Cancers · doi:10.3390/cancers18071064

MicroRNA spatial profiling for assessing drug efficacy in BRCA1-related triple-negative breast tumorsPreprint

Mohd, O. N., Wang, L., Sardella, B., Jou, D., Wulf, G. M., Slack, F. J., Heng, Y. J., & Doyle, P. S. (2026) · eLife · doi:10.7554/elife.112264

MicroRNA spatial profiling for assessing drug efficacy in BRCA1-related triple-negative breast tumorsPreprint

Mohd, O. N., Wang, L., Sardella, B., Jou, D., Wulf, G. M., Slack, F. J., Heng, Y. J., & Doyle, P. S. (2026) · eLife · doi:10.7554/elife.112264.1

Abstract IA08: PI3K- and PARP-inhibitors for the treatment of women cancers.

Wulf, G. M., Juvekar, A., Cantley, L. C., & Matulonis, U. A. (2016) · Clinical Cancer Research · doi:10.1158/1557-3265.ovca15-ia08

Abstract 2650: PI 3-Kinase inhibitors enhance the synthetic lethality of Parp inhibitors

Juvekar, A., Yadegarynia, S., Hu, H., Lyssiotis, C. A., Liu, H., Asara, J. M., Scully, R., Cantley, L. C., & Wulf, G. M. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2650

Abstract CT338: Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer

Wulf, G. M., Juvekar, A., Lyssiotis, C. A., Hu, H., Yadegarynia, S., Liu, H., Kim, B., Winter, E., Scully, R., Asara, J. M., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct338 · Cited by 2 · see citing works

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465 · see citing works

Abstract 3746: PI3K inhibition sensitizes to PARP inhibitors in patient-derived xenograft models of triple negative breast cancer

Ibrahim, Y. H., García-García, C., Serra, V., Scaltriti, M., Juric, D., Antón, P., Guzmán, M., Cozar, P., Aura, C. M., Jimenez, J., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3746 · Cited by 1 · see citing works